Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,865Revenue (TTM) $M5.8Net Margin (%)--Altman Z-Score--
Enterprise Value $M--EPS (TTM) $-6.3Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M37.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GEVAGeorge Soros 2013-12-31 Sold Out -0.01%$45.51 - $69.69
$ 238.60303%Sold Out0
GEVAGeorge Soros 2013-09-30 Buy 0.01%$43.26 - $62.55
$ 238.60386%New holding17,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GEVA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

GEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Williams GlenSVP, Technical Operations 2015-06-08Sell12,916$214.9211.02view
Williams GlenSVP, Technical Operations 2015-05-06Sell1,666$205.6216.04view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-27Sell10,000$110116.91view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-21Sell10,000$108120.93view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-15Sell10,000$105127.24view
Williams GlenSVP, Technical Operations 2015-04-08Sell42,632$96.08148.33view
Quinn AnthonyEVP, CMO & Head of R&D 2015-04-06Sell29,503$93.76154.48view
Heberlig ChrisSVP, Finance and Business Ops. 2015-03-11Sell7,500$103.17131.27view
BOESS CARSTENSVP, CFO 2015-02-17Sell42,297$100.11138.34view
BAKER FELIXDirector, 10% Owner 2015-01-07Buy1,000,000$94.19153.32view

Quarterly/Annual Reports about GEVA:

    News about GEVA:

    Articles On GuruFocus.com
    Columbia Wanger Sells 22 Stakes in Second Quarter Aug 17 2015 
    Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
    Wednesday Pre-Market Insights: GEVA, BRDR, MGI, NDLS, ZU May 06 2015 

    More From Other Websites
    Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
    Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
    The Only Way to Play Biotech Buyouts Jun 09 2015
    Why These 4 Biotech Stocks Could Be the Next Buyout Targets May 07 2015
    Rich Synageva M&A premium epitomizes appetite for orphan drugs May 06 2015
    Alexion Pharma to pay $8.4 billion for Synageva BioPharma May 06 2015
    Is Alexion Grossly Overpaying for Synageva? May 06 2015
    Alexion Pharma to buy Synageva BioPharma for $8.4 bln May 06 2015
    Synageva BioPharma reports 1Q loss Apr 29 2015
    Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
    Synageva BioPharma reports 4Q loss Feb 26 2015
    New Year, New Biotech Stock Offerings -- Lots of 'Em Jan 05 2015
    Biotech Bull Markets and Billion-Dollar Valuations Dec 23 2014
    Synageva BioPharma beats 3Q profit forecasts Oct 31 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)